Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Equities research analysts at Wedbush upped their Q1 2018 earnings estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.16) per share for the quarter, up from their previous forecast of ($0.46). Wedbush also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.62) EPS, Q3 2018 earnings at ($0.58) EPS, Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($2.00) EPS, FY2019 earnings at ($2.21) EPS, FY2020 earnings at ($1.95) EPS and FY2021 earnings at ($1.79) EPS.
SYRS has been the subject of a number of other reports. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. HC Wainwright reaffirmed a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Oppenheimer reaffirmed a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 7th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Roth Capital started coverage on shares of Syros Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $22.23.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.53).
Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors grew its stake in shares of Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after acquiring an additional 5,016 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Syros Pharmaceuticals in the third quarter worth approximately $133,000. Cubist Systematic Strategies LLC bought a new stake in shares of Syros Pharmaceuticals in the third quarter worth approximately $149,000. The Manufacturers Life Insurance Company grew its stake in shares of Syros Pharmaceuticals by 11,253.8% in the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after acquiring an additional 10,466 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Syros Pharmaceuticals in the second quarter worth approximately $198,000. Hedge funds and other institutional investors own 57.96% of the company’s stock.
In other news, Director Srinivas Akkaraju bought 109,774 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was acquired at an average cost of $9.03 per share, with a total value of $991,259.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeremy P. Springhorn bought 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/13/syros-pharmaceuticals-inc-syrs-expected-to-earn-q1-2018-earnings-of-0-16-per-share.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.